Who Exports Bortezomib from India — 200 Suppliers Behind a $21.9M Market
India's bortezomib export market is supplied by 200 active exporters who collectively shipped $21.9M across 1,383 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 32.0% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and MSN LABORATORIES PRIVATE LIMITED. The top 5 suppliers together control 74.4% of total export value, reflecting a concentrated market structure.
Top Bortezomib Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading bortezomib exporter from India, holding a 32.0% share of the $21.9M market across 1,383 shipments from 200 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, VENUS REMEDIES LIMITED, FRESENIUS KABI ONCOLOGY LIMITED — collectively control 74.4% of total export value, indicating a highly concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (32.0%), EUGIA PHARMA SPECIALITIES LIMITED (18.4%), MSN LABORATORIES PRIVATE LIMITED (16.4%), VENUS REMEDIES LIMITED (4.0%), FRESENIUS KABI ONCOLOGY LIMITED (3.7%).
Top Bortezomib Exporters from India
Ranked by export value · 200 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $7.0M | 5 | 32.0% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED BORTEZOMIB FOR INJECTION 3.5 MG/VIAL - US)BORTEZOMIB FOR INJECTION 3.5 MG/VIAL (BOBORTEZOMIB 3.5MG IV/SC INJ 1'S USA | $4.0M | 10 | 18.4% |
| 3 | MSN LABORATORIES PRIVATE LIMITED ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $3.6M | 20 | 16.4% |
| 4 | VENUS REMEDIES LIMITED BORTEZOMIB FRESENIUS KABI INJECTION 3.5MBORTEZOMIB FRESENIUS KABI INJ. 3.5MG/VIABORTEZOMIB FRESENIUS KABI INJ. 3.5MG/VIAL, | $864.3K | 16 | 4.0% |
| 5 | FRESENIUS KABI ONCOLOGY LIMITED EXFUCIKANET INJ 3.5MGEXFUCIKANET INJ 3.5MG3143VLS60.85BORTEZOMIB FRESENIUS KABI INJECTION 3.5M | $803.7K | 10 | 3.7% |
| 6 | DR REDDYS LABORATORIES LIMITED ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $755.8K | 6 | 3.5% |
| 7 | DR.REDDY'S LABORATORIES LTD ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $569.0K | 2 | 2.6% |
| 8 | GLENMARK PHARMACEUTICALS LIMITED ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $377.2K | 2 | 1.7% |
| 9 | SP ACCURE LABS PRIVATE LIMITED BORTEZOMIB FOR INJECTION 3.5 MG/VIAL - US)BORTEZOMIB FOR INJECTION 3.5 MG/VIAL (BOBORTEZOMIB 3.5MG IV/SC INJ 1'S USA | $315.0K | 6 | 1.4% |
| 10 | GLAND PHARMA LIMITED BORTEZOMIB FOR INJECTION 3.5 MG/VIAL - US)BORTEZOMIB FOR INJECTION 3.5 MG/VIAL (BOBORTEZOMIB 3.5MG IV/SC INJ 1'S USA | $264.6K | 2 | 1.2% |
| 11 | VEXXA LIFESCIENCES PVT. LTD. BORTESUM INJ 3.5MG 1S VL PH (BORTEZOMIBBORTESUM INJ 3.5MG 1S NOSBORVEX 3.5 | $166.6K | 1 | 0.8% |
| 12 | UNITED BIOTECH PRIVATE LIMITED | $143.6K | 4 | 0.7% |
| 13 | MILES INTERNATIONAL BORTEZOMIB DR. REDDYS 3.5MG/VIAL 1S UKBORTEZOMIB FOR INJECTION 3.5MG/VIAL-UK)BORTEZOMIB FOR INJECTION 3.5 MG/VIAL - UK) | $129.4K | 3 | 0.6% |
| 14 | RELIANCE LIFE SCIENCES PRIVATE LIMITED ZOMI EACH CONTAINS BORTEZOMIB,BN-HAE0029ZOMI EACH CONTAINS BORTEZOMIB PACK : 01*BORTEZOMIB FOR INJECTION 3.5 MG/VIAL. BO | $125.3K | 4 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bortezomib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified as of February 2015. |
| EUGIA PHARMA SPECIALITIES LIMITED | Not Listed | Yes, as of November | No | Not verified | WHO-GMP certified as of November 2025. |
| MSN LABORATORIES PRIVATE LIMITED | Approved | Yes, as of February | No | 1 | FDA-approved ANDA for Lacosamide; WHO-GMP certified as of February 2015. |
| VENUS REMEDIES LIMITED | Not Listed | Yes, as of November | No | Not verified | WHO-GMP certified as of November 2025. |
| GLENMARK PHARMACEUTICALS LIMITED | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified as of February 2015. |
| DR. REDDY'S LABORATORIES LIMITED | Approved | Yes, as of February | No | Not verified | FDA-approved; WHO-GMP certified as of February 2015. |
| GLAND PHARMA LIMITED | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified as of February 2015. |
| SP ACCURE LABS PRIVATE LIMITED | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified as of February 2015. |
TransData Nexus reviewed the regulatory standing of 8 leading Bortezomib exporters from India. 2 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bortezomib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," is a pivotal hub for bulk drug production. The city contributes nearly 40% of the country's bulk drug output and hosts over 2,000 pharmaceutical companies. This concentration is bolstered by initiatives like the Hyderabad Pharma City project, aimed at creating a comprehensive ecosystem for pharmaceutical manufacturing and research. Notably, companies such as Gland Pharma, headquartered in Hyderabad, have been instrumental in the production and export of Bortezomib.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its prowess in pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output. The region is home to major pharmaceutical firms like Alembic Pharmaceuticals, which has a significant presence in Vadodara. These companies are key players in the formulation and export of Bortezomib, leveraging the region's robust infrastructure and skilled workforce.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Mumbai's strategic coastal location and well-established port facilities facilitate the efficient export of drugs like Bortezomib to international markets. The region's proximity to major shipping routes and its comprehensive logistics network enhance its role in the global pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. These incentives have attracted numerous pharmaceutical companies, contributing to the production of various drugs, including Bortezomib. The region's growth underscores the impact of policy measures in shaping industrial landscapes.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Cluster Specializations: Utilize Hyderabad for bulk drug procurement and Ahmedabad-Vadodara for formulations to optimize the supply chain.
- Monitor Export Logistics: Ensure robust logistics planning when exporting through the Mumbai-Thane-Raigad corridor to maintain timely deliveries.
- Stay Informed on Policy Changes: Keep abreast of tax incentives and regulatory shifts in regions like Baddi-Nalagarh to capitalize on cost-saving opportunities.
By strategically aligning sourcing strategies with the strengths of India's pharmaceutical clusters, companies can enhance the efficiency and resilience of their Bortezomib supply chains.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bortezomib exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma Completes Taro Merger
Sun Pharma completed the merger with Taro Pharmaceutical Industries Ltd., acquiring all outstanding ordinary shares of Taro, making it a wholly-owned subsidiary. - IMPACT: This consolidation may enhance Sun Pharma's manufacturing capabilities, potentially increasing Bortezomib production and export capacity.
Impact: This consolidation may enhance Sun Pharma's manufacturing capabilities, potentially increasing Bortezomib production and export capacity.
Eugia Pharma Specialities Limited — Aurobindo Pharma Plans Eugia Pharma IPO to Raise Rs 4,500 Crore
Aurobindo Pharma is exploring an IPO for its subsidiary, Eugia Pharma Specialities, aiming to raise approximately Rs 4,500 crore to enhance operational efficiency and fund strategic initiatives. - IMPACT: The capital infusion could bolster Eugia's production capabilities, potentially increasing Bortezomib exports.
Impact: The capital infusion could bolster Eugia's production capabilities, potentially increasing Bortezomib exports.
Sun Pharmaceutical Industries Limited — FDA Issues Warning Letter to Sun Pharma
The FDA issued a warning letter to Sun Pharma for significant violations of Current Good Manufacturing Practice regulations at its Dadra facility, including inadequate cleaning and maintenance of equipment. - IMPACT: Addressing these regulatory concerns may temporarily affect Bortezomib production and export schedules.
Impact: Addressing these regulatory concerns may temporarily affect Bortezomib production and export schedules.
Common Questions — Bortezomib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bortezomib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 57 recorded shipments worth $7.0M. EUGIA PHARMA SPECIALITIES LIMITED (69 shipments) and MSN LABORATORIES PRIVATE LIMITED (97 shipments) are also established high-volume exporters.
Q How many bortezomib manufacturers are there in India?
India has 200 active bortezomib exporters with a combined export market of $21.9M across 1,383 shipments to 109 countries. The top 5 suppliers hold 74.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bortezomib from India?
Average FOB unit price: $37.04 per unit, ranging from $0.05 to $1081.57. Average shipment value: $15.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 200 verified Indian exporters of Bortezomib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,383 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 109 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,383 Verified Shipments
200 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists